塞来昔布治疗疼痛及炎症临床前期及临床研究

[1] AmericanCollegeofRheumatologypreliminarydefinitionofimprovementinrheuma toidarthritis. FelsonDT,AndersonJJ,BoersM,etal. Arthritis and Rheumatism . 1995

[2] Limitedanti in flamma toryefficacyofcycol oxygenase 2inhibitionincarrageenan air pouchinflammation. WallaceJL,ChapmanK,McKnightW. British Journal of Pharmacology . 1999

[3] Theclinicalimplicationsofinhibitionoftheinducibleformofcyclo oxygenase. RichardsonC,EmeryP. DrugSafety . 1996

[4] Qualityim provementguidelinesforthetreatmentofacutepainandcancerpain. AmericanPainSocietyQualityofCareCommittee. The Journal of The American Medical Association . 1995

[5] ArthritisFactSheet. ArthritisFoundation. . 1999

[6] PreliminarystudyofthesafetyandefficacyofSC 5 86 35anovelcyclooxygenase 2in hibitor. SimonLS,LanzaFL,LipskyPE,etal. Arthritis and Rheumatism . 1998

[7] Developmentofcriteriafortheclassificationandreportingofosteoarthritis:classificationofos teoarthritisoftheknee. AltmanR,AschE,BlochG,etal. Arthritis and Rheumatism . 1986

[8] ThediscoveryandfunctionofCOX 2. NeedlemanP,IsaksonPC. JRheumatol,1997,2 4(Suppl49)∶ .

[9] SC 5 86 35 ,ahighlyselectiveinhibitorofCOX 2 ,isaneffectiveanalgesicinanacutepostsurgicalpainmode. HubardRC,MehischDR,JasperDR,etal. JInvestMed . 1996

[10] ValidationstudyofWOMAC :ahealthstatusinstru mentformeasuringclinicallyimportantpatientrelevantoutcomestoantirheumaticdrugtherapyinpatientswithosteoarthritisofthehiporknee. BellamyN. The Journal of Rheumatology . 1988

[1] AmericanCollegeofRheumatologypreliminarydefinitionofimprovementinrheuma toidarthritis. FelsonDT,AndersonJJ,BoersM,etal. Arthritis and Rheumatism . 1995

[2] Limitedanti in flamma toryefficacyofcycol oxygenase 2inhibitionincarrageenan air pouchinflammation. WallaceJL,ChapmanK,McKnightW. British Journal of Pharmacology . 1999

[3] Theclinicalimplicationsofinhibitionoftheinducibleformofcyclo oxygenase. RichardsonC,EmeryP. DrugSafety . 1996

[4] Qualityim provementguidelinesforthetreatmentofacutepainandcancerpain. AmericanPainSocietyQualityofCareCommittee. The Journal of The American Medical Association . 1995

[5] ArthritisFactSheet. ArthritisFoundation. . 1999

[6] PreliminarystudyofthesafetyandefficacyofSC 5 86 35anovelcyclooxygenase 2in hibitor. SimonLS,LanzaFL,LipskyPE,etal. Arthritis and Rheumatism . 1998

[7] Developmentofcriteriafortheclassificationandreportingofosteoarthritis:classificationofos teoarthritisoftheknee. AltmanR,AschE,BlochG,etal. Arthritis and Rheumatism . 1986

[8] ThediscoveryandfunctionofCOX 2. NeedlemanP,IsaksonPC. JRheumatol,1997,2 4(Suppl49)∶ .

[9] SC 5 86 35 ,ahighlyselectiveinhibitorofCOX 2 ,isaneffectiveanalgesicinanacutepostsurgicalpainmode. HubardRC,MehischDR,JasperDR,etal. JInvestMed . 1996

[10] ValidationstudyofWOMAC :ahealthstatusinstru mentformeasuringclinicallyimportantpatientrelevantoutcomestoantirheumaticdrugtherapyinpatientswithosteoarthritisofthehiporknee. BellamyN. The Journal of Rheumatology . 1988